Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Pharmacokinetic analysis of nacubactam, a novel β-lactamase inhibitor, co-administered with meropenem in patients with a complicated urinary tract infection
Saved in:
| Published in: | JAC-Antimicrobial Resistance |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Pharmacokinetic analysis of nacubactam, a novel β-lactamase inhibitor, co-administered with meropenem in patients with a complicated urinary tract infection
- In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan
- Update on the comparative in vitro activity of cefiderocol and four β-lactam–β-lactamase-inhibitor combinations against clinically important Gram-negative pathogens
- Bacteremic versus Non-Bacteremic Urinary Tract Infections: Predictors of Poor Clinical Outcome
- Therapeutic strategies for multi-resistant Escherichia coli in urinary tract infections—a cause for concern
- Correction to: Therapeutic strategies for multi-resistant Escherichia coli in urinary tract infections—a cause for concern
- Carbapenem resistance in community-acquired urinary tract infections caused by Klebsiella pneumoniae and Escherichia coli in Morocco: a multicentre study (January 2022–December 2023)‘Carbapenem resistance in community UTIs in Morocco’